Actively Recruiting
Dual-energy SPEctral CT to Evaluate Response to First-line Therapies in Patients With Metastatic Clear Cell REnal Cancer
Led by IRCCS Azienda Ospedaliero-Universitaria di Bologna · Updated on 2025-03-07
50
Participants Needed
2
Research Sites
152 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
To evaluate the utility of dual-energy spectral computed tomography (CT) scan in monitoring treatment in patients with metastatic clear cell carcinoma of the kidney. In particular, to analyze the use of spectral CT in patients who are candidates to receive first-line treatment based on combinations of immunotherapy and molecularly targeted drugs. In particular, the parameters derived from the use of this technology and their variation during therapy will be analyzed together with some possible molecular alterations highlighted by the analysis of the tumor tissue previously taken from the patient, relating them to the response to first-line therapy with immuno-combinations.
CONDITIONS
Official Title
Dual-energy SPEctral CT to Evaluate Response to First-line Therapies in Patients With Metastatic Clear Cell REnal Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 63; 18 years
- Histological or cytological diagnosis of clear cell renal cell carcinoma
- Metastatic disease confirmed by imaging or biopsy of secondary site
- No previous treatment for renal cell carcinoma
- Indication for first-line treatment with immunotherapy plus tyrosine kinase inhibitors or immunotherapy combinations
- Dual-energy spectral total-body CT performed within 4 weeks before treatment start
- Availability of stored tumor tissue for molecular analysis of specified gene alterations
- Signed informed consent to participate in the study
You will not qualify if you...
History of severe allergic reactions to study medication Currently pregnant or breastfeeding Recent participation in another clinical trial within the last 30 days Presence of uncontrolled medical conditions that could affect safety
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Irccs Azienda Ospedaliero Universitario Di Bologna
Bologna, BO, Italy, 40138
Actively Recruiting
2
Oncology Unit, IRCCS Azienda Ospedaliero Universitaria Bologna
Bologna, Italy, 40138
Actively Recruiting
Research Team
F
Francesco FM Massari, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here